Patients with RA in remission on TNF blockers: when and in whom can TNF blocker therapy be stopped?
Patients with RA in remission on TNF blockers: when and in whom can TNF blocker therapy be stopped?
复制标题
DOI：
10.1136/ard.2009.117341
复制
发表时间：
2010-09-01
影响因子：
27.4
通讯作者：
Emery, Paul
中科院分区：
文献类型：
--
作者：
Saleem, Benazir;Keen, Helen;Emery, Paul
目的联合应用甲氨蝶呤（MTX）和肿瘤坏死因子（TNF）阻断剂可提高类风湿关节炎（RA）患者的缓解率。然而，没有关于停止治疗的指导方针。有必要对TNF阻断剂治疗停止后持续缓解的预测指标。
Objectives Combination therapy with methotrexate (MTX) and tumour necrosis factor (TNF) blockade has increased remission rates in patients with rheumatoid arthritis. However, there are no guidelines regarding cessation of therapy. There is a need for markers predictive of sustained remission following cessation of TNF blocker therapy.Methods Patients in remission (DAS28